Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
Remdesivir is an approved antiviral treatment for COVID-19, but it needs to be administered intravenously. Here, Cox et al. show that GS-621763, a prodrug of remdesivir parent nucleoside GS-441524 has good oral bioavailability and inhibits SARS-CoV-2 and variants of concerns in ferrets.
Enregistré dans:
Auteurs principaux: | Robert M. Cox, Josef D. Wolf, Carolin M. Lieber, Julien Sourimant, Michelle J. Lin, Darius Babusis, Venice DuPont, Julie Chan, Kim T. Barrett, Diane Lye, Rao Kalla, Kwon Chun, Richard L. Mackman, Chengjin Ye, Tomas Cihlar, Luis Martinez-Sobrido, Alexander L. Greninger, John P. Bilello, Richard K. Plemper |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/480b9bcf109e47b7bd2093b34d9f4683 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
par: Maria L. Agostini, et autres
Publié: (2018) -
Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524
par: Daniela Krentz, et autres
Publié: (2021) -
The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance
par: Daisy Yan, et autres
Publié: (2021) -
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
par: Timothy P. Sheahan, et autres
Publié: (2020) -
Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus
par: Travis K. Warren, et autres
Publié: (2021)